Phaseline

Targets › HCRT

HCRT (Hypocretin neuropeptide precursor): drug programs, companies and trials

3 programs from 3 companies in 10 trials: 7 Phase 2, 3 Phase 3; Neurology; next expected readout Nov 2026.

Neuropeptides that play a significant role in the regulation of food intake and sleep-wakefulness, possibly by coordinating the complex behavioral and physiologic responses of these complementary homeostatic functions. A broader role in the homeostatic regulation of energy metabolism, autonomic function, hormonal balance and the regulation of body fluids, is also suggested..; FUNCTION: [Orexin-A]: Binds to orexin…. (UniProt, O43612)

Open in Phaseline: the race on HCRT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AlkermesALKS 2680
Hypocretin/orexin pathway modulator
HCRTPhase 3Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic HypersomniaNov 2026
TakedaTAK-360
Orexin receptor agonist
HCRTPhase 2Idiopathic Hypersomnia; Narcolepsy Type 2; Narcolepsy Type 1Nov 2026
Centessa Pharmaceuticals (UK)cleminorexton
Orexin receptor agonist
HCRTPhase 2Narcolepsy Type 1Sep 2027

Conditions

Narcolepsy Type 1 (5) Idiopathic Hypersomnia (3) Narcolepsy Type 2 (2)

Modalities

small molecule (3)

Companies

Alkermes (1) Takeda (1) Centessa Pharmaceuticals (UK) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.